Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Colitis, Ulcerative 1

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × NX-13 × 1 year × Clear all
NCT05785715 2025-07-01

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

AbbVie

Phase 2 Terminated
81 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡